STUDY COURSES Sample Clauses

STUDY COURSES. 22.01 The Employer shall contribute up to fifty per cent (50%) of the cost of study courses approved by it that directly increase an employee’s work qualifications. Each request for such assistance is considered on its merits and shall not be arbitrarily withheld. For French or English courses located in Canada or Saint-Pierre-Miquelon, subject to advance approval of the course by the Employer, the Employer will pay one hundred (100%) of the cost of the tuition and required textbooks. An employee who fails to complete the course shall reimburse the Employer. In the event that the approved course is a full-time immersion course over a period of weeks, the Employer will provide the attending employee a leave of absence with pay at this basic salary for one-half (½) the length of such course. If any such course is located elsewhere, the Employer shall not be obliged to pay any part of the cost of such course but will pay the basic salary of the attending employee for one-half (½) the length of such course up to a maximum of four (4) weeks of basic salary.
Sample 1Sample 2Sample 3See All (10)
AutoNDA by SimpleDocs
STUDY COURSES. Automobiles . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Sample 1
STUDY COURSES. 22.01 The Employer shall contribute up to fifty per cent (50%) of the cost of study courses approved by it that directly increase an em- - 4 3 - work qualifications. Each request for such assistance is con- sidered on its merits and shall not be arbitrarily withheld. For French or English courses located in Canada or subject to advance approval of the course by the Employer, the Employer will pay one hundred of the cost of the tuition and required textbooks. An employee who fails to complete the course shall reimburse the Employer. In the event that the approved course is a full-time immersion course over a period of weeks, the Employer will provide the attending employee a leave of absence with pay at this basic salary for one-half the length of such course. If any such course is located elsewhere, the Employer shall not be obliged to pay any part of the cost of such course but will pay the basic salary of the attending employee for one-half the length of such course up to a maximum of four weeks of basic salary. Technicians may indicate in writing to their Department Head or designate their desire to receive training courses in equipment serv- iced by employees.
Sample 1
STUDY COURSES. ITE328 Supply Chain Management and Freight Forwarding 3 ECTS Supply chain management and its basic principles. SCM models and their application. The role of information in freight forwarding. Delivery time and accuracy assessment. The role of time in determination of the quality of deliveries. Evaluation of delivery delay. IĀS734 Organization of International Purchasing Process 3 ECTS Study course provides an overview of an international purchasing process, its planning, establishing, management and control. It pays attention to the key factors, such as, suppliers’ evaluation and awarding, cooperation, cost efficiency, process efficiency. It helps the student to have a solid ground underneath when choosing one supplier and not the other, based on the financial benefits for his/her the company. IĀS411 International Marketing 3 ECTS International Marketing course gives a basic outlook of marketing methods and tools used in international marketing, as well as their practical application, analysis and evaluation of results. The course gives an overview of marketing theories, their significance in marketing nowadays and shows the development of future communications in international marketing. It also provides an outlook on different product and service markets and their anthropological differences, communication types and methods. It shows the basics of branding and brand management. IĀS720 Intercultural Communication 3 ECTS This course provides the basis for understanding potential problems of intercultural communication that arise in interactions between people from different cultures, contributes the understanding regarding communication barriers and the possible solutions how to overcome them. During the study course students will have possibility to obtain skills how to interpret cultural diversity, to predict behavior of business partners, to get awareness of importance of business etiquette and, on the bases of acquired knowledge, to develop own communication strategy. IĀS732 The European Union Governance and Policy 4.5 ECTS The study course provides an insight into the creation of the European Union, the competences and legal system, explains the organization of the European Union institutions, functions and the process of decision-making, introduces the European Union’s policies relating to the economy and business. IRE404 Current Trends of the European Union Economic Policy 3 ECTS The course contains theoretical information on approaches and forms of...
Sample 1

Related to STUDY COURSES

  • Training Courses 16.3.1 Training courses will be as described in the Seller’s customer services catalog (the “Seller’s Customer Services Catalog”). The Seller’s Customer Services Catalog also sets forth the minimum and maximum number of trainees per course. All training requests or training course changes made outside of the scope of the Training Conference will be submitted by the Buyer with a minimum of ***** prior notice.

  • Trials The Ship shall run the following test and trials:

  • Courses A. Any course that is contained within the common course numbering system shall be eligible if not specifically excluded by Florida Statute, State Board of Education Rule, District Board of Trustees Policy, or District Board of Education Policy. College-level courses including mathematics, English, science, foreign language, social sciences and social studies, vocational courses, and such other courses as may be mutually agreed upon shall be offered by the College for high school students participating in the program. To ensure transferability of credits, students’ educational plans should be closely evaluated when utilizing specialty courses for dual enrollment. To further ensure transferability, North Florida Community College encourages students to concentrate on general education courses. Students who intend to earn an associate in arts or baccalaureate degree should carefully evaluate each course to determine its applicability to meeting degree requirements.

  • Activities Except with the prior written consent of the Board, Executive will not during his employment with the Company undertake or engage in any other employment, occupation or business enterprise, other than ones in which Executive is a passive investor. Executive may engage in civic and not-for-profit activities so long as such activities do not materially interfere with the performance of his duties hereunder.

  • Other Activities Your services pursuant to this Agreement shall not be deemed to be exclusive, and you may render similar services and act as an underwriter, distributor or dealer for other investment companies in the offering of their shares.

  • Vaccinations Contractor understands, acknowledges, and agrees that, pursuant to Article II of the General Appropriations Act, none of the General Revenue Funds appropriated to the Department of State Health Services (DSHS) may be used for the purpose of promoting or advertising COVID-19 vaccinations in the 2024-25 biennium. It is also the intent of the legislature that to the extent allowed by federal law, any federal funds allocated to DSHS shall be expended for activities other than promoting or advertising COVID-19 vaccinations. Contractor represents and warrants that it is not ineligible, nor will it be ineligible during the term of this Contract, to receive appropriated funding pursuant to Article II.

  • Vaccination and Inoculation (a) The Employer agrees to take all reasonable precautions, including in-service seminars, to limit the spread of infectious diseases among employees.

  • Studies The clinical, pre-clinical and other studies and tests conducted by or on behalf of or sponsored by the Company or its subsidiaries that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus were and, if still pending, are being conducted in accordance in all material respects with all statutes, laws, rules and regulations, as applicable (including, without limitation, those administered by the FDA or by any foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA). The descriptions of the results of such studies and tests that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus are accurate and complete in all material respects and fairly present the published data derived from such studies and tests, and each of the Company and its subsidiaries has no knowledge of other studies or tests the results of which are materially inconsistent with or otherwise call into question the results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, neither the Company nor its subsidiaries has received any notices or other correspondence from the FDA or any other foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA with respect to any ongoing clinical or pre-clinical studies or tests requiring the termination or suspension of such studies or tests. For the avoidance of doubt, the Company makes no representation or warranty that the results of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company will be sufficient to obtain governmental approval from the FDA or any foreign, state or local governmental body exercising comparable authority.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Medications Psychotropic medications and medications associated with treating a diagnosed mental health condition.

Time is Money Join Law Insider Premium to draft better contracts faster.